Coronado commences TSO trial in pediatric patients with autism spectrum disorder.
M2 EQUITYBITES-April 14, 2014-Coronado commences TSO trial in pediatric patients with autism spectrum disorder
(C)2014 M2 COMMUNICATIONS http://www.m2.com
Coronado Biosciences (CNDO), a US-based bioscences company, has started an investigator-initiated trial evaluating TSO (Trichuris suis ova or CNDO-201) for the treatment of paediatric patients with autism spectrum disorder (ASD), it was reported on Friday.
Dr. Itai Berger, director of the Neuro-Cognitive Center at the Hadassah-Hebrew University Medical Center in Jerusalem, Israel, is carrying out the trial.
The trial is intended to test the safety of TSO compared to a placebo in approximately 60 paediatric patients between the ages of 6 and 17 years who meet criteria for the diagnosis of ASD and efficacy signals on irritability, repetitive behaviours, global functioning and social cognition.
In the 16-week randomised, double-blind, placebo-controlled trial, patients will receive a placebo, 2500 TSO or 7500 TSO every other week.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Apr 14, 2014|
|Previous Article:||Quad/Graphics prices private offering of USD300m senior notes due 2022.|
|Next Article:||Intapp takes over risk management software firm TFG.|